BofA Securities initiated coverage on Caris Life Sciences with a new price target
$CAI
Medical Specialities
Health Care
BofA Securities initiated coverage of Caris Life Sciences with a rating of Buy and set a new price target of $31.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/2/2026 | Peer Perform | Wolfe Research | |
| 4/13/2026 | $28.00 | Buy | Jefferies |
| 4/10/2026 | $21.00 | Neutral | Piper Sandler |
| 4/1/2026 | $27.00 | Buy | Goldman |
| 2/17/2026 | $26.00 | Outperform | Robert W. Baird |
| 12/2/2025 | $28.00 | Hold | Canaccord Genuity |
| 7/14/2025 | $31.00 | Buy | BofA Securities |
| 7/14/2025 | $31.00 | Overweight | Analyst |
IRVING, Texas, July 16, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading TechBio company, today announced it will report second quarter 2026 financial results on Wednesday, August 5, 2026. Caris Life Sciences will host a live webcast at 3:30 p.m. CT (4:30 p.m. ET) to discuss the financial results.Webcast Details:Date: Wednesday, August 5, 2026Time: 3:30 p.m. CT (4:30 p.m. ET)Live Webcast: https://edge.media-server.com/mmc/p/ff8xb4qsA replay of the webcast will be available shortly after the conclusion of the call on the Investor Relations section of the Caris Life Sciences website at CarisLifeSciences.com.About
IRVING, Texas, July 14, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading patient-centric next-generation AI TechBio company and precision medicine pioneer, today announced it will offer in-house PTEN immunohistochemistry (IHC) testing following the recent FDA approval of a biomarker-guided therapy and companion diagnostic assay. This testing is designed to help identify patients with PTEN-deficient metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer (previously known as metastatic hormone-sensitive prostate cancer) who are eligible for the newly approved biomarker-guided therapy, representing a significant advancement in precision oncology fo
Ultra-deep Whole Genome and Whole Transcriptome sequencing combined with sophisticated AI algorithmsdelivers superior performance to existing cancer detection technologiesIRVING, Texas, July 1, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced the commercial launch of Caris Detect™, a groundbreaking multi-cancer early detection blood test designed to uncover cancer signals at earlier, more treatable stages. Caris Detect is engineered to push the boundaries of what is possible in early cancer detection. Using ultra
4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
4 - Caris Life Sciences, Inc. (0002019410) (Issuer)
CERT - Caris Life Sciences, Inc. (0002019410) (Filer)
8-A12B - Caris Life Sciences, Inc. (0002019410) (Filer)
8-K - Caris Life Sciences, Inc. (0002019410) (Filer)
Wolfe Research resumed coverage of Caris Life Sciences with a rating of Peer Perform
Jefferies initiated coverage of Caris Life Sciences with a rating of Buy and set a new price target of $28.00
Piper Sandler initiated coverage of Caris Life Sciences with a rating of Neutral and set a new price target of $21.00
IRVING, Texas, July 16, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading TechBio company, today announced it will report second quarter 2026 financial results on Wednesday, August 5, 2026. Caris Life Sciences will host a live webcast at 3:30 p.m. CT (4:30 p.m. ET) to discuss the financial results.Webcast Details:Date: Wednesday, August 5, 2026Time: 3:30 p.m. CT (4:30 p.m. ET)Live Webcast: https://edge.media-server.com/mmc/p/ff8xb4qsA replay of the webcast will be available shortly after the conclusion of the call on the Investor Relations section of the Caris Life Sciences website at CarisLifeSciences.com.About
Revenue growth of 79% driven by strong performance in molecular profiling servicesIRVING, Texas, May 7, 2026 /PRNewswire/ -- Caris Life Sciences, Inc. (NASDAQ:CAI), a leading, patient centric, next-generation AI TechBio company and precision medicine pioneer, today reported financial results for the quarter ended March 31, 2026. First Quarter 2026 Financial HighlightsReported total revenue of $216.2 million, an increase of 79% over the corresponding prior year period.Completed approximately 52,800 clinical therapy selection cases, an increase of approximately 15% over the corres
IRVING, Texas, April 20, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ:CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced it will report first quarter 2026 financial results on Thursday, May 7, 2026. Caris Life Sciences will host a live webcast at 3:30 p.m. CT (4:30 p.m. ET) to discuss the financial results.Webcast Details:Date: Thursday, May 7, 2026Time: 3:30 p.m. CT (4:30 p.m. ET)Live Webcast: https://edge.media-server.com/mmc/p/6iwr2xf8/A replay of the webcast will be available shortly after the conclusion
SC 13G/A - CAI International, Inc. (0001388430) (Subject)
SC 13G - CAI International, Inc. (0001388430) (Subject)
SC 13G - CAI International, Inc. (0001388430) (Subject)